KO-2806-001 KO-2806-001: Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination The

NCT06026410

KO-2806-001: Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients with Advanced Solid Tumors

Associated Conditions

Multiple Tumor Types

Principal Investigator

Guru Sonpavde

Sponsor

Kura Oncology, Inc.

The purposes of this study are to:
• Determine the highest tolerable dose of KO-2806 given orally (by mouth) in combination with cabozantinib.
• Determine whether KO-2806 has an antitumor effect (reduces the size of your tumor and slows down the growth of your cancer) in combination with cabozantinib to treat patients who have your type of cancer.

Other reasons for conducting the study are to determine how long KO-2806 stays in your blood stream, how your body breaks it down, and how the drug affects your body.

This study is currently enrolling.